EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PMDA Perspective on RWD / RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage

Kazuhiro Kajiyama, Maki Komamine iD, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama iD

Pharmacoepidemiology and Drug Safety · 2024-09 · 33 (9)

DOI: 10.1002/pds.70007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 06.09.2024. Verfasst von Kazuhiro Kajiyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Hauptthemen laut MEDLINE: Product Surveillance, Postmarketing. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Product Surveillance, PostmarketingHumansDrug-Related Side Effects and Adverse ReactionsRisk AssessmentPharmacoepidemiologyAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationUnited States

Stichwörter der Autor:innen

drug safetypharmacoepidemiologyregulatory decisionssafety measures

Autor:innen und Institutionen

  • Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Regulatory Science Research, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

ORCID-Profile: Maki Komamine, Yoshiaki Uyama

Zitieren

APA

Kajiyama, K., Komamine, M., Horiuchi, N., Iguchi, T., & Uyama, Y. (2024). PMDA Perspective on RWD / RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage. Pharmacoepidemiology and Drug Safety, 33(9). https://doi.org/10.1002/pds.70007

Vancouver

Kajiyama K, Komamine M, Horiuchi N, Iguchi T, Uyama Y. PMDA Perspective on RWD / RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage. Pharmacoepidemiology and Drug Safety. 2024;33(9). doi:10.1002/pds.70007

BibTeX
@article{Kajiyama2024,
  author = {Kajiyama, Kazuhiro and Komamine, Maki and Horiuchi, Naoya and Iguchi, Toyotaka and Uyama, Yoshiaki},
  title = {PMDA Perspective on RWD / RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  volume = {33},
  number = {9},
  doi = {10.1002/pds.70007}
}
Kostenlos starten →